Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
France Targets Shein, Temu With Fast-Fashion Fees 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Add as a preferred source on Google
SOUTH SAN FRANCISCO, Calif., March 15, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on March 12, 2018, the compensation committee of the Company’s board of directors granted David L. Johnson an option to purchase 55,000 shares of the Company’s common stock with a per share exercise price of $54.05, the closing trading price on the grant date, and a restricted stock unit award for 35,000 shares of the Company’s common stock. All of the above-described awards were made under the Company’s 2017 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement material to Mr. Johnson entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Company has reserved an aggregate of 300,000 shares of its common stock (including the shares underlying the stock options and restricted stock unit awards described above) for issuance under the Plan, which was approved by the Company’s board of directors in January 2017.
About Global Blood Therapeutics
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
[email protected]
Julie Normart (media)
W2O pure
415-946-1087
[email protected]
